Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C

[Business Wire] – Gilead Sciences, Inc. today announced that Health Canada has issued a Notice of Compliance for Harvoni™ , the first once-daily single table regimen for the treatment of chronic hepatitis C . . . → Read More: Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Stock Update: Gilead Sciences Inc (NASDAQ:GILD) – England agrees funding for Gilead hepatitis C drug